{"entity":{"id":"i-mab","kind":"company","name":"I-Mab","aka":["I-Mab Biopharma","天境生物","NASDAQ:IMAB"],"tldr":"I-Mab is a biotech, founded in Shanghai and now based in Maryland, whose Claudin 18.2 and 4-1BB bispecific givastomig and CD73 antibody uliledlimab are in trials for stomach and lung cancer.","summary":"I-Mab develops immuno-oncology biologics and moved its headquarters to Rockville, Maryland after separating from its Chinese operations in 2024. Givastomig (TJ-CD4B), a Claudin 18.2 and 4-1BB bispecific, is in phase 1b/2 trials with nivolumab and chemotherapy in first-line gastric cancer. Uliledlimab (TJ004309) is a differentiated CD73 antibody studied with toripalimab in non-small cell lung cancer. The company also developed lemzoparlimab, a CD47 antibody once licensed to AbbVie.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.i-mabbiopharma.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["uliledlimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Rockville, Maryland","country":"US","companyType":"biotech","website":"https://www.i-mabbiopharma.com/","ticker":"NASDAQ:IMAB","founded":2016,"stage":"public","investors":[],"funding":[]},"route":"/companies/i-mab/","neighbours":{"drug":[{"id":"uliledlimab","kind":"drug","name":"Uliledlimab","route":"/drugs/uliledlimab/"}]}}